Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06389357 | Retun-to-school Adaptation Program for Children With Cancer(web-based) | completed | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04710043 | Dose Escalation Trial of BNT152+153 in Patients With Cancer | completed | Phase 1 | 86 | BioNTech SEINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT06073951 |
| Evaluation of a Couple-Based Physical Activity Intervention |
| completed |
| N/A |
| 96 |
| Mayo ClinicOTHER |
| 1 |
| Sep 24, 2025 |
| clinicaltrials |
| NCT06063603 | Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study | completed | N/A | 51 | Mayo ClinicOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05072106 | Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | completed | Phase 1 | 11 | PharmaMarINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05109832 | A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects | completed | Phase 1 | 6 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05390944 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition | completed | Phase 1 | 28 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05391048 | An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition | completed | Phase 1 | 36 | Impact Therapeutics, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05989997 | Phase I Clinical Trial of 68Ga-NOTA-SNA002 | completed | Phase 1 | 17 | SmartNuclide BiopharmaINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 37 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03944499 | Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. | completed | Phase 1 | 161 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04446260 | A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 5 | Sep 15, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05161390 | Study of LM-302 in Patients With Advance Solid Tumors | completed | Phase 1 / Phase 2 | 153 | LaNova Medicines Zhejiang Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05199753 | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 78 | LaNova Australia Pty LimitedINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07167095 | 90-Day Mortality After Emergency Department Discharge in Advanced Cancer(CARE-90) | completed | — | 1,250 | Ankara Etlik City HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04889144 | PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning | completed | N/A | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05063318 | Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | PharmaMarINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05114668 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00712712 | Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer(MEDOR) | completed | Phase 2 | 78 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04564027 | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 3 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT05014828 | To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors | completed | Phase 2 | 58 | BeiGeneINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT04970992 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Da Zen Theranostics IncINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05494918 | First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors | completed | Phase 1 | 62 | Alphamab (Australia) Co Pty Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT03084757 | SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)(SHIVA02) | completed | N/A | 170 | Institut CurieOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03762447 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | completed | Phase 1 | 138 | Incyte CorporationINDUSTRY | 5 | Aug 11, 2025 | clinicaltrials |
| NCT04487236 | Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors | completed | Phase 1 | 61 | Suzhou Zanrong Pharma LimitedINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02220556 | Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology(CTC-CEC-ADN) | completed | N/A | 360 | Institut CurieOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05685472 | MEDI5752 in Japanese Patients With Advanced Solid Tumors. | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02836600 | A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06231550 | A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 21 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT03410121 | Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy(PACPAC-EPOC) | completed | N/A | 361 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02628574 | Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | completed | Phase 1 | 109 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | completed | Phase 1 | 325 | Incyte CorporationINDUSTRY | 16 | Aug 3, 2025 | clinicaltrials |
| NCT06048367 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor(CNSI-Fe(II)) | completed | Phase 1 | 19 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | completed | Phase 1 | 174 | ALX Oncology Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02428712 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | completed | Phase 1 / Phase 2 | 113 | Fore BiotherapeuticsINDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04306900 | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | completed | Phase 1 | 185 | Trishula Therapeutics, Inc.INDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT05391022 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | completed | Phase 1 | 35 | Constellation PharmaceuticalsINDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT03654547 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | completed | Phase 1 | 48 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 2 | Jul 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 29, 2025source: clinicaltrials